Crizotinib, the “first generation” (1G) TKI used for the treatment of ALK‐positive NSCLC, was approved by the US FDA in 2011 [23] and by the UK NICE in 2014 [24]. This evidence concerns the gene ALK and non-small cell lung carcinoma.